NCT01332552: A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects |
|
|
| Terminated | 1 | 27 | US | GSK2485852 70 mg, GSK2485852 420 mg, placebo, GSK2485852 630 mg, GSK2485852 70 mg + Ritonavir 100mg, GSK2485852 210 mg + Ritonavir 100mg, GSK2485852 210 mg +Ritonavir 100mg | GlaxoSmithKline | Hepatitis C | 04/11 | 04/11 | | |
